CMS Issues the List of Selected Drugs for Initial Price Applicability Year 2027
CMS Issues the List of Selected Drugs for Initial Price Applicability Year 2027
- On January 17, 2025, the Centers for Medicare & Medicaid Services (CMS) issued the list of 15 additional Part D drugs for the Medicare Drug Price Negotiation Program.
- The drugs selected for this negotiation are:
- Ozempic or Rybelsus or Wegovy;
- Trelegy Ellipta;
- Xtandi;
- Pomalyst;
- Ibrance;
- Ofev;
- Linzess;
- Calquence;
- Austedo or Austedo XR;
- Breo Ellipta;
- Tradjenta;
- Xifaxan;
- Vraylar;
- Janumet or Janumet XR; and
- Otezla.
- The new prices will go into effect on January 1, 2027.
- Four drugs qualified for the small biotech exception.
- These selected drugs accounted for about $40.7 billion in total gross covered Part D prescription drug costs, or about 14% of total gross covered Part D prescription drug costs, between November 2023 and October 2024.
- For 2028, CMS will select up to 15 more drugs covered by Part B or Part D and up to 20 more Part B or Part D drugs for each year after that.
For questions, please reach out to Vicky Jucelin.
Related
In January 2025, the U.S. Department of Health and Human Services (HHS) issued a Strategic Plan for the Use of Artificial Intelligence in Health, Human Services, and Public Health in efforts to use AI responsibly to improve people's lives.
On December 20, 2024, the Centers for Medicare & Medicaid Services (CMS) issued explanations for the maximum fair prices (MFPs) for the drugs selected for the IRA’s Medicare Drug Price Negotiation Program for the initial price applicability year (IPAY) 2026.
On Dec. 12, 2024, the Centers for Medicare and Medicaid Services (CMS) issued a final rule titled, “Modifications of Health Insurance Portability and Accountability Act of 1996 (HIPAA) National Council for Prescription Drug Programs (NCPDP) Retail Pharmacy Standards; and Modification of the Medicaid Pharmacy Subrogation Standard” (Final Rule).
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
